Publication:
Evolution of Serum Acute-Phase Glycoproteins Assessed by 1H-NMR in HIV Elite Controllers

dc.contributor.authorMalo, Ana-Irene
dc.contributor.authorPeraire, Joaquim
dc.contributor.authorRuiz-Mateos, Ezequiel
dc.contributor.authorMasip, Jenifer
dc.contributor.authorAmigó, Núria
dc.contributor.authorAlcamí, José
dc.contributor.authorMoreno, Santiago
dc.contributor.authorGirona, Josefa
dc.contributor.authorGarcía-Pardo, Graciano
dc.contributor.authorReig, Rosaura
dc.contributor.authorVidal, Francesc
dc.contributor.authorCastro, Antoni
dc.contributor.authorMasana, Lluís
dc.contributor.authorRull, Anna
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderRed de Investigación Cooperativa en Investigación en Sida (España)es_ES
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)
dc.contributor.funderRovira i Virgili University (España)
dc.contributor.funderInstitut d Investigació Sanitària Pere Virgili (España)
dc.contributor.funderAgència de Gestió d´Ajuts Universitaris i de Recerca (AGAUR)
dc.date.accessioned2022-05-05T09:54:33Z
dc.date.available2022-05-05T09:54:33Z
dc.date.issued2021-09
dc.description.abstractElite controllers (ECs) are an exceptional group of people living with HIV (PLWH) who maintain undetectable viral loads (VLs) despite not being on antiretroviral therapy (ART). However, this phenotype is heterogeneous, with some of these subjects losing virological control over time. In this longitudinal retrospective study, serum acute-phase glycoprotein profile assessed by proton nuclear magnetic resonance (1H-NMR) was determined in 11 transient controllers (TCs) who spontaneously lost virological control and 11 persistent controllers (PCs) who persistently maintained virological control over time. Both PCs and TCs showed similar acute-phase glycoprotein profiles, even when TCs lost the virological control (GlycB, p = 0.824 and GlycA, p = 0.710), and the serum acute-phase glycoprotein signature in PCs did not differ from that in HIV-negative subjects (GlycB, p = 0.151 and GlycA, p = 0.243). Differences in serum glycoproteins A and B were significant only in ECs compared to HIV-typical progressors (TPs) with < 100 CD4+ T-cells (p < 0.001). 1H-NMR acute-phase glycoprotein profile does not distinguish TCs form PCs before the loss of viral control. ECs maintain a low-grade inflammatory state compared to TPs. PCs revealed a closer serum signature to HIV-negative subjects, reaffirming this phenotype as a closer model of functional control of HIV.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis research was funded by the Fondo de Investigacion Sanitaria [PI16/00503, PI19/01337 and PI20/00326]-ISCIII-FEDER (co-funded by the European Regional Development Fund/European Social Fund; “A way to make Europe”/“Investing in your future”); Programa de Suport als Grups de Recerca AGAUR (2017SGR948); the SPANISH AIDS Research Network [RD12/0017/0005, RD12/0025/0001, RD16/0025/0006]-ISCIII-FEDER (Spain) and Centro de Investigación Biomédica en Red de Enfermedades Infecciosas-ISCIII [CB21/13/00015, CB21/13/00020, CB13/21/00086], Madrid, Spain. JM is supported by the Universitat Rovira i Virgili under grant agreement “2019PMF-PIPF-18,” through the call “Martí Franquès Research Fellowship Programme”. FV is supported by grants from the Programa de Intensificación de Investigadores (INT20/00031)-ISCIII. AR is supported by a grant from IISPV through the project “2019/IISPV/05” (Boosting Young Talent), by GeSIDA through the “III Premio para Jóvenes Investigadores 2019” and by the Instituto de Salud Carlos III (ISCIII) under grant agreement “CP19/00146” through the Miguel Servet Program.es_ES
dc.format.page730691es_ES
dc.format.volume12es_ES
dc.identifier.citationFront Immunol. 2021 Sep 28;12:730691.es_ES
dc.identifier.doi10.3389/fimmu.2021.730691es_ES
dc.identifier.e-issn1664-3224es_ES
dc.identifier.journalFrontiers in Immunologyes_ES
dc.identifier.pubmedID34650556es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14260
dc.language.isoenges_ES
dc.publisherFrontiers Media
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//RD12%2F0017%2F0005/ES/SIDA/es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RD12/0025/0001es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//RD16%2F0025%2F0006/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)/es_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/Subprograma Estatal de Generación de Conocimiento/Proyectos de investigacion en salud (AES 2016). Modalidad proyectos en salud. (2016)/PI16/00503es_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/Subprograma Estatal de Generación de Conocimiento/PI19 - Proyectos de investigacion en salud (AES 2019). Modalidad proyectos en salud. (2019)/PI19/01337es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI20/00326es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CP19/00146es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CB21/13/00015es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CB21/13/00020es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CB13/21/00086es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/INT20/00031es_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fimmu.2021.730691es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectHIVes_ES
dc.subjectAcute-phase glycoproteinses_ES
dc.subjectElite controllerses_ES
dc.subjectInflammationes_ES
dc.subjectProton nuclear magnetic resonancees_ES
dc.titleEvolution of Serum Acute-Phase Glycoproteins Assessed by 1H-NMR in HIV Elite Controllerses_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication2fc55aca-54b0-411c-b170-c2149068a902
relation.isAuthorOfPublication.latestForDiscovery2fc55aca-54b0-411c-b170-c2149068a902
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication0b5a6d3a-4d4d-4346-9bcc-9359bbe13e72
relation.isFunderOfPublicationf236c6af-7ac3-49fe-8a6a-818b321c6130
relation.isFunderOfPublication04af3075-1932-48dc-b284-b08bf9ebb154
relation.isFunderOfPublicationaf365449-d1bb-4678-af42-7483b561cd83
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublication9f9fa5ea-093b-43d8-bf2c-5bd65d08a802
relation.isPublisherOfPublication.latestForDiscovery9f9fa5ea-093b-43d8-bf2c-5bd65d08a802

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
EvolutionOfSerumAcute_2021.pdf
Size:
949.25 KB
Format:
Adobe Portable Document Format
Description:
Artículo principal
Loading...
Thumbnail Image
Name:
EvolutionOfSerumAcuteSupplementaryMaterial_2021.pdf
Size:
141.51 KB
Format:
Adobe Portable Document Format
Description:
Supplementary Information